Obermatt
See Similar Stocks →

Flags

Earnings warning

Heidelberg Pharma

GER:HPHA · DE000A11QVV0
BiotechnologySmall

360

32
Profit price71
Owner Earnings Yield1
Dividend Yield1
Price/Sales26
EV / Gross Profit27
Price/Book83
Returns on capital6
Profit margins51
Accruals67
Owner Earnings Margin17
Sales growth80
Profit growth42
Reinvestment4
Price momentum11
Debt load50
Refinancing76
Debt Payback1
Liquidity1
Analyst ratings53
Opinion Changes50
Price Target Upside34
Market mood75
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Heidelberg Pharma doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryGermany
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeXTRA
Employees47
Websiteheidelberg-pharma.com
ISINDE000A11QVV0
Last UpdateApr 2, 2026
Indices
CDAX (Germany)
Themes
Health DiagnosticsHematologyInfectious DiseasesOncologyBiotechnologyHealth CarePharmaceutical

Description

Heidelberg Pharma AG is a biotechnology company that specializes in the development and commercialization of innovative therapies based on antibody-drug conjugates (ADCs). The company focuses primarily on utilizing its proprietary technology platform…

Analysis

Middle-of-the-road

Heidelberg Pharma AG sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 0/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
16
2026

All-time high

26

Mar 2026

All-time low

16

Jun 2026

Average rank

21

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
26
—
—
—
Price/Earnings
47
—
—
—
Price/Book
83
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
51
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Heidelberg Pharma with its peers
Immatics
NAQ:IMTX
31
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tiziana Life Sciences
NAQ:TLSA
67
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Inventiva
PAR:IVA
16
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Alkermes
NSQ:ALKS
36
CountryIreland
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Genmab
CPH:GMAB
40
CountryDenmark
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Molecular Partners
SWX:MOLN
1
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →